Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorraine A Fitzpatrick

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
The Journal of Clinical Endocrinology and Metabolism|November 13, 2004
Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery diseasePeter Y Liu, Rose C Christian, Ming Ruan, et al.
Bone Reports|December 5, 2019
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendChad L Deal, Bruce H Mitlak, Yamei Wang, et al.
Advances in Experimental Medicine and Biology|October 31, 2007
RANKL inhibition: from mice to men (and women)Marina Stolina, Paul J Kostenuik, William C Dougall, et al.
Mayo Clinic Proceedings|February 13, 2004
Genetic determinants of arterial calcification associated with atherosclerosisTerence M Doherty, Lorraine A Fitzpatrick, Aisha Shaheen, et al.
Calcified Tissue International|December 30, 2017
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with AbaloparatideMichael R McClung, Gregory C Williams, Gary Hattersley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 10, 2016
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk FactorsFelicia Cosman, Gary Hattersley, Ming-Yi Hu, et al.
Mayo Clinic Proceedings|August 14, 2002
Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisisSimona Dionisi, Salvatore Minisola, Jessica Pepe, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2006
Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal womenRose C Christian, Peter Y Liu, Sean Harrington, et al.
Seminars in Arthritis and Rheumatism|February 10, 2019
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fractureMickael Hiligsmann, Setareh A Williams, Lorraine A Fitzpatrick, et al.
Calcified Tissue International|February 1, 2018
Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with AbaloparatideMichael R McClung, Gregory C Williams, Gary Hattersley, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Endocrinology and Metabolism|November 13, 2004
Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery diseasePeter Y Liu, Rose C Christian, Ming Ruan, et al.
Bone Reports|December 5, 2019
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendChad L Deal, Bruce H Mitlak, Yamei Wang, et al.
Advances in Experimental Medicine and Biology|October 31, 2007
RANKL inhibition: from mice to men (and women)Marina Stolina, Paul J Kostenuik, William C Dougall, et al.
Mayo Clinic Proceedings|February 13, 2004
Genetic determinants of arterial calcification associated with atherosclerosisTerence M Doherty, Lorraine A Fitzpatrick, Aisha Shaheen, et al.
Calcified Tissue International|December 30, 2017
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with AbaloparatideMichael R McClung, Gregory C Williams, Gary Hattersley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 10, 2016
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk FactorsFelicia Cosman, Gary Hattersley, Ming-Yi Hu, et al.
Mayo Clinic Proceedings|August 14, 2002
Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisisSimona Dionisi, Salvatore Minisola, Jessica Pepe, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 2006
Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal womenRose C Christian, Peter Y Liu, Sean Harrington, et al.
Seminars in Arthritis and Rheumatism|February 10, 2019
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fractureMickael Hiligsmann, Setareh A Williams, Lorraine A Fitzpatrick, et al.
Calcified Tissue International|February 1, 2018
Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with AbaloparatideMichael R McClung, Gregory C Williams, Gary Hattersley, et al.
Pageof 7